CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Science and medicine are incredibly amazing. Thanks to modern science and medicine, we now have lifespans far beyond our Dark Age predecessors, living until ripe old age and enjoying the fruits of our ...

CRISPR Therapeutics recently reported that rollout of its approved gene therapy Casgevy for sickle cell disease and transfusion‑dependent beta thalassemia has been slower than hoped, contributing to a ...

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...

Whales with a lot of money to spend have taken a noticeably bearish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 13 trades. If we ...

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.